JP2023542296A5 - - Google Patents

Info

Publication number
JP2023542296A5
JP2023542296A5 JP2023516479A JP2023516479A JP2023542296A5 JP 2023542296 A5 JP2023542296 A5 JP 2023542296A5 JP 2023516479 A JP2023516479 A JP 2023516479A JP 2023516479 A JP2023516479 A JP 2023516479A JP 2023542296 A5 JP2023542296 A5 JP 2023542296A5
Authority
JP
Japan
Prior art keywords
inhibitor
gene mutation
gene
fgfr3
fgfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023516479A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542296A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/075145 external-priority patent/WO2022053697A1/en
Publication of JP2023542296A publication Critical patent/JP2023542296A/ja
Publication of JP2023542296A5 publication Critical patent/JP2023542296A5/ja
Pending legal-status Critical Current

Links

JP2023516479A 2020-09-14 2021-09-13 Fgfr阻害剤の併用療法 Pending JP2023542296A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063078193P 2020-09-14 2020-09-14
US63/078,193 2020-09-14
PCT/EP2021/075145 WO2022053697A1 (en) 2020-09-14 2021-09-13 Fgfr inhibitor combination therapies

Publications (2)

Publication Number Publication Date
JP2023542296A JP2023542296A (ja) 2023-10-06
JP2023542296A5 true JP2023542296A5 (cg-RX-API-DMAC7.html) 2024-09-26

Family

ID=77821784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516479A Pending JP2023542296A (ja) 2020-09-14 2021-09-13 Fgfr阻害剤の併用療法

Country Status (10)

Country Link
US (1) US20230321087A1 (cg-RX-API-DMAC7.html)
EP (1) EP4210702A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542296A (cg-RX-API-DMAC7.html)
KR (1) KR20230069958A (cg-RX-API-DMAC7.html)
CN (1) CN116669763A (cg-RX-API-DMAC7.html)
AU (1) AU2021339962A1 (cg-RX-API-DMAC7.html)
CA (1) CA3191538A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023002980A (cg-RX-API-DMAC7.html)
TW (1) TW202228695A (cg-RX-API-DMAC7.html)
WO (1) WO2022053697A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202308689A (zh) * 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
WO2005110076A2 (en) 2004-05-10 2005-11-24 Children's Medical Center Corporation Braf expression in zebrafish and uses thereof
AU2005250484B2 (en) 2004-06-04 2011-08-11 Genentech, Inc. EGFR mutations
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
SG11201702381QA (en) 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
EP3929190B1 (en) 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
EA201792205A1 (ru) * 2015-04-03 2018-02-28 Инсайт Корпорейшн Гетероциклические соединения как ингибиторы lsd1
MA43416A (fr) * 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
WO2018213297A1 (en) * 2017-05-16 2018-11-22 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies
KR20250047324A (ko) * 2017-08-07 2025-04-03 더 존스 홉킨스 유니버시티 암을 평가하고 치료하기 위한 방법 및 재료
WO2020131627A1 (en) * 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
US20220175768A1 (en) * 2019-03-29 2022-06-09 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
WO2020208592A1 (en) * 2019-04-12 2020-10-15 Dr. Reddy’S Laboratories Limited Process for preparation of erdafitinib, its purification and amorphous solid dispersion
CN111420060B (zh) * 2020-03-30 2022-04-08 南方医科大学南方医院 一种抗肿瘤的联合用药组合物及其应用

Similar Documents

Publication Publication Date Title
Tao et al. Cancer associated fibroblasts: An essential role in the tumor microenvironment
US9242000B2 (en) Micro-RNAs and micro-RNA inhibitors to modulate blood vessel growth, patterning, tumor growth and malignant disease and method for making and using them
Diaz-Rubio et al. Capecitabine (Xeloda®) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors
JP2018508469A5 (cg-RX-API-DMAC7.html)
CN111032082B (zh) Her2阳性癌症的治疗
US11633401B2 (en) Combination therapy with MEK inhibitor and CDK4/6 inhibitor to treat pancreatic cancer
JP7520366B2 (ja) 腫瘍療法の副作用の予防または治療方法
Symonds et al. Combined targeted therapies for first-line treatment of metastatic triple negative breast cancer—a phase II trial of weekly nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib
US20230404971A1 (en) Combination Comprising Abemaciclib and 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid
CN110996927A (zh) 复发性胶质母细胞瘤(rgbm)的治疗方法
JP2022527482A5 (cg-RX-API-DMAC7.html)
JP2022505647A (ja) 腫瘍の処置方法
Gordon et al. Phase I open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of dilpacimab in patients with advanced solid tumors
Zhou et al. The present roles and future perspectives of Interleukin-6 in biliary tract cancer
CN117919234A (zh) 一种萘酰胺化合物治疗耐药性肿瘤的用途
JP2023513298A5 (cg-RX-API-DMAC7.html)
CN107949401A (zh) 联合施用酪氨酸激酶抑制剂来抑制表皮生长因子/表皮生长因子受体途径的方法及组合物
JP2022527189A5 (cg-RX-API-DMAC7.html)
US20230097085A1 (en) [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer
US20220348662A1 (en) Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings
TW201521742A (zh) 具降低毒性之庫司替森(custirsen)療法
Leong et al. Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats
WO2021073535A1 (zh) 预防或治疗与vegfr和/或vegf被抑制相关疾病的方法
US20210379095A1 (en) Methods and Combination Therapy to Treat Biliary Tract Cancer
US20230102483A1 (en) [6r]-mthf in 5-fu based chemotherapy of left-sided colorectal cancer